Stockreport

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility [Yahoo! Finance]

Pfizer, Inc.  (PFE) 
Last pfizer, inc. earnings: 4/28 06:45 am Check Earnings Report
PDF Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative t [Read more]